 Gefitinib application once per day caused “rapid” symptom improvement and tumor regressions in non-small cell lung cancer patients.In the field of medical research, this is an especially significant example of the use of an inhibitor to treat tyrosine kinase-associated cancer.Chemotherapy, surgery, and radiotherapy were the only major options available prior to the discoveries made in this trial.